This Apidra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to the increasing global prevalence of diabetes, advancements in insulin analog formulations, the adoption of personalized diabetes management technologies, regulatory approvals, market expansion into new regions, improvements in insurance reimbursement, and better access to treatment.
Growth during the market's forecast period is driven by factors such as the rising number of diabetes diagnoses, advancements in insulin delivery technologies, expansion into emerging markets, biosimilar competition following patent expirations, and a growing emphasis on personalized medicine. Key trends in the forecast period include the increased adoption of digital health solutions, the shift towards automated insulin delivery systems, rising demand for biosimilars, a focus on patient-centric treatment approaches, and the expansion of healthcare infrastructure in developing regions.
The increasing prevalence of diabetes is anticipated to drive the growth of the apidra market in the future. Diabetes is a chronic condition in which the body is unable to regulate blood sugar (glucose) levels effectively. The rising prevalence of diabetes, fueled by factors such as aging populations, sedentary lifestyles, and growing obesity rates, has led to higher demand for rapid-acting insulin treatments such as Apidra. Apidra (insulin glulisine) helps diabetes patients by swiftly controlling blood sugar levels after meals, mimicking the body’s natural insulin response, and providing flexibility in managing the condition to reduce the risk of hyperglycemia and enhance overall glycemic control. For example, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%. Furthermore, the percentage achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is driving the growth of the apidra market.
The increasing incidence of obesity is expected to further accelerate the growth of the apidra market. Obesity is a condition characterized by excessive body fat accumulation that can impair health and elevate the risk of chronic diseases. The growing prevalence of obesity is attributed to factors such as sedentary lifestyles, unhealthy eating habits, genetic predisposition, and environmental influences. Apidra aids in managing obesity-related diabetes by effectively controlling blood sugar, supporting overall weight management in individuals with insulin resistance or type 2 diabetes. For instance, in 2022, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that 22 states now have an adult obesity prevalence of 35% or higher, up from 19 states in 2021. Therefore, the rising incidence of obesity is driving the growth of the apidra market.
The increasing focus on personalized medicine is expected to fuel the growth of the apidra market. Personalized medicine refers to medical treatment tailored to individual characteristics, such as genetic makeup, lifestyle, and environment, to maximize effectiveness and minimize side effects. This approach is made possible by advances in genomics, biotechnology, and data analytics, allowing healthcare providers to customize treatments based on an individual’s genetic profile, lifestyle, and environmental factors. Apidra supports personalized medicine by enabling customized diabetes management plans, offering precise control of blood sugar levels based on an individual’s unique dietary habits, activity levels, and glucose patterns. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the apidra market.
The key company operating in the apidra market is Sanofi S.A.
North America was the largest region in the apidra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in apidra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the apidra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Apidra is a rapid-acting insulin analog (insulin glulisine) used to help manage blood sugar levels in individuals with diabetes. It begins working quickly after injection, typically within 15 minutes, and is taken before meals to control spikes in blood sugar after eating. Apidra is often prescribed in combination with long-acting insulin or other medications as part of a comprehensive diabetes management plan.
The primary indications for apidra are type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune disorder in which the immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in little or no insulin production. The distribution channels for Apidra include hospital pharmacies, drug stores, retail pharmacies, and online providers, with end users including hospitals, clinics, ambulatory care settings, and home care environments.
The apidra market research report is one of a series of new reports that provides apidra market statistics, including apidra industry global market size, regional shares, competitors with a apidra market share, detailed apidra market segments, market trends, and opportunities, and any further data you may need to thrive in the apidra industry. This apidra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The apidra market consists of sales of Apidra SoloStar Pen, Apidra vial, and Apidra cartridge. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to the increasing global prevalence of diabetes, advancements in insulin analog formulations, the adoption of personalized diabetes management technologies, regulatory approvals, market expansion into new regions, improvements in insurance reimbursement, and better access to treatment.
Growth during the market's forecast period is driven by factors such as the rising number of diabetes diagnoses, advancements in insulin delivery technologies, expansion into emerging markets, biosimilar competition following patent expirations, and a growing emphasis on personalized medicine. Key trends in the forecast period include the increased adoption of digital health solutions, the shift towards automated insulin delivery systems, rising demand for biosimilars, a focus on patient-centric treatment approaches, and the expansion of healthcare infrastructure in developing regions.
The increasing prevalence of diabetes is anticipated to drive the growth of the apidra market in the future. Diabetes is a chronic condition in which the body is unable to regulate blood sugar (glucose) levels effectively. The rising prevalence of diabetes, fueled by factors such as aging populations, sedentary lifestyles, and growing obesity rates, has led to higher demand for rapid-acting insulin treatments such as Apidra. Apidra (insulin glulisine) helps diabetes patients by swiftly controlling blood sugar levels after meals, mimicking the body’s natural insulin response, and providing flexibility in managing the condition to reduce the risk of hyperglycemia and enhance overall glycemic control. For example, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%. Furthermore, the percentage achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is driving the growth of the apidra market.
The increasing incidence of obesity is expected to further accelerate the growth of the apidra market. Obesity is a condition characterized by excessive body fat accumulation that can impair health and elevate the risk of chronic diseases. The growing prevalence of obesity is attributed to factors such as sedentary lifestyles, unhealthy eating habits, genetic predisposition, and environmental influences. Apidra aids in managing obesity-related diabetes by effectively controlling blood sugar, supporting overall weight management in individuals with insulin resistance or type 2 diabetes. For instance, in 2022, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that 22 states now have an adult obesity prevalence of 35% or higher, up from 19 states in 2021. Therefore, the rising incidence of obesity is driving the growth of the apidra market.
The increasing focus on personalized medicine is expected to fuel the growth of the apidra market. Personalized medicine refers to medical treatment tailored to individual characteristics, such as genetic makeup, lifestyle, and environment, to maximize effectiveness and minimize side effects. This approach is made possible by advances in genomics, biotechnology, and data analytics, allowing healthcare providers to customize treatments based on an individual’s genetic profile, lifestyle, and environmental factors. Apidra supports personalized medicine by enabling customized diabetes management plans, offering precise control of blood sugar levels based on an individual’s unique dietary habits, activity levels, and glucose patterns. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the apidra market.
The key company operating in the apidra market is Sanofi S.A.
North America was the largest region in the apidra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in apidra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the apidra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Apidra is a rapid-acting insulin analog (insulin glulisine) used to help manage blood sugar levels in individuals with diabetes. It begins working quickly after injection, typically within 15 minutes, and is taken before meals to control spikes in blood sugar after eating. Apidra is often prescribed in combination with long-acting insulin or other medications as part of a comprehensive diabetes management plan.
The primary indications for apidra are type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune disorder in which the immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in little or no insulin production. The distribution channels for Apidra include hospital pharmacies, drug stores, retail pharmacies, and online providers, with end users including hospitals, clinics, ambulatory care settings, and home care environments.
The apidra market research report is one of a series of new reports that provides apidra market statistics, including apidra industry global market size, regional shares, competitors with a apidra market share, detailed apidra market segments, market trends, and opportunities, and any further data you may need to thrive in the apidra industry. This apidra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The apidra market consists of sales of Apidra SoloStar Pen, Apidra vial, and Apidra cartridge. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Apidra Market Characteristics4. Apidra Market Trends and Strategies5. Apidra Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Apidra Pricing Analysis & Forecasts30. Global Apidra Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Apidra Market32. Recent Developments in the Apidra Market
3. Apidra Market Biologic Drug Characteristics
6. Global Apidra Growth Analysis and Strategic Analysis Framework
8. Apidra Market Segmentation
9. Global Apidra Epidemiology of Clinical Indications
10. Apidra Market Regional and Country Analysis
11. Asia-Pacific Apidra Market
12. China Apidra Market
13. India Apidra Market
14. Japan Apidra Market
15. Australia Apidra Market
16. South Korea Apidra Market
17. Western Europe Apidra Market
18. UK Apidra Market
19. Germany Apidra Market
20. France Apidra Market
21. Eastern Europe Apidra Market
22. North America Apidra Market
23. USA Apidra Market
24. Canada Apidra Market
25. South America Apidra Market
26. Middle East Apidra Market
27. Africa Apidra Market
28. Apidra Market Competitive Landscape and Company Profiles
29. Global Apidra Market Pipeline Analysis
33. Apidra Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Apidra Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on apidra market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for apidra? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The apidra market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Type 1 Diabetes; Type 2 Diabetes2) by Distribution Channel: Hospital Pharmacies; Drug Stores & Retail Pharmacies; Online Provider
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Sanofi S.a.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
